NDT Advance Access originally published online on May 29, 2008
Nephrology Dialysis Transplantation 2008 23(10):3372; doi:10.1093/ndt/gfn263
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reply
Nephrol Dial Transplant 2008; doi:10.1093/ndt/gfn251E-mail: schaefe{at}uni-muenster.de
Sir,
We appreciate the interest of O. Vaage-Nilsen who claims that in our article [1] we had not distinguished between high-molecular-weight (Dexferrum®) and low-molecular-weight (INFed®) dextran. This of course is not the case. We were quoting an article by Chertow et al. [2], of which Mr Vaage-Nilsen is an author as well, clearly showing that the reported numbers of life-threatening events over a 3-year period were 6/10.000.000 with iron sucrose versus 33/10.000.000 for the INFed iron dextran. Rare events indeed, but still a striking difference nonetheless. For these reasons the European Best Practice Guidelines—published in this learned journal do discourage the use of all iron dextran species, irrespective of their molecular weight [3].
Conflict of interest statement. None declared.
1 Institute of Pharmacology and Toxicology, University of Frankfurt Frankfurt 2 Department of Medicine University of Muenster Muenster Germany
References
- Schaefer L, Schaefer RM. A primer on iron therapy. Nephrol Dial Transplant (2007) 2:2429–2431.
- Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant (2006) 21:378–382.
[Abstract/Free Full Text] - Locatelli F, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 19(Suppl_2):ii1–47.
[Free Full Text]
Related articles in NDT:
- Editorial Note
- N. Lameire
NDT 2008 23: 1-3.[Extract] [FREE Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||